Stocks Health care CERO
OTC · Health careCero Therapeutics Holdings, Inc. (CERO)
It posted a net loss of $16.3M. At June 30, 2026 it held $862.8K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Cero Therapeutics Holdings, Inc.
- Net worth
- Cero Therapeutics Holdings, Inc. has a market value (market cap) of $250.7K at the latest share price, and shareholders' equity of -$30.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $16.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cero Therapeutics Holdings, Inc.'s next report is expected around November 18, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Cero Therapeutics Holdings, Inc. declared dividends of $10.37 per share in fiscal 2025, a yield of 296,285.71% at the current price.
What Cero Therapeutics Holdings, Inc. does
Cero Therapeutics Holdings, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker CERO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$19.9M | n/a | n/a |
| 2023 | n/a | -$7.3M | -$1,248.64 | n/a |
| 2022 | n/a | -$667.7K | n/a | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Dividends
Cero Therapeutics Holdings, Inc. declared $10.37 per share in fiscal 2025. At the current price that is a yield of 296,285.71%. It paid out $127.1K in cash dividends.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $10.37 | $127.1K | n/a |
Latest SEC filings
What Cero Therapeutics Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 31, 2026
- August 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- July 17, 2026
- July 13, 2026Delisting notice 25-NSE
- June 26, 2026
- May 29, 2026
- May 15, 2026
- May 1, 2026
- April 30, 2026
Insider trades
What the people running Cero Therapeutics Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns CERO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| YK Bioventures Opportunities Fund I, L.P. (F/K/A YK Bioventures, LLC)13G, passive with 3 related filers | 15% | November 14, 2024 |
| Stuart Sloan13G, passive with 1 related filers | 14% | November 20, 2024 |
| Brian G. Atwood13D, may seek influence with 2 related filers | 9.9% | April 4, 2025 |
| Lawrence Corey13G, passive | 5.7% | December 13, 2024 |
Largest institutional holders
Insiders
Questions about CERO
What does Cero Therapeutics Holdings, Inc. do?
Cero Therapeutics Holdings, Inc. is a company in the Health care sector, listed on OTC as CERO. Its shares trade on OTC under the ticker CERO.
What is Cero Therapeutics Holdings, Inc.'s net worth?
Cero Therapeutics Holdings, Inc. has a market value (market cap) of $250.7K at the latest share price, and shareholders' equity of -$30.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cero Therapeutics Holdings, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $16.3M.
When did Cero Therapeutics Holdings, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from August 31, 2026.
When is Cero Therapeutics Holdings, Inc.'s next earnings report?
Cero Therapeutics Holdings, Inc.'s next report is expected around November 18, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Does Cero Therapeutics Holdings, Inc. pay a dividend?
Yes. Cero Therapeutics Holdings, Inc. declared dividends of $10.37 per share in fiscal 2025, a yield of 296,285.71% at the current price.
Similar companies
Compare CERO with
Follow CERO
Get an email when Cero Therapeutics Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cero Therapeutics Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.